Alticast Corporation Overview
Headquarters address note:
-
S&P lists "Park Building, Seoul 06655" (postal code 06655 is in Seocho-gu).
-
Jasoseol (public data aggregator) lists 4F, 12 Teheran-ro 7-gil, Gangnam-gu, Seoul (Yeoksam-dong, Heoba-Heoba Building).
The discrepancy is unresolved; the current registered address should be confirmed against the latest DART filing.
Trend: A verified three-year trend is not publicly disclosed in sources reviewed.
Group headcount: This figure (including Daehyun Gigeon and Aptamer Sciences) is not disclosed in sources reviewed.
Alticast is no longer the pure-play broadcast software house that listed on KOSDAQ in 2013. That franchise covered middleware, conditional access and DRM for Korean IPTV and cable operators. It was carved out and sold to KT in 2021.
After three years of shrinking software revenue and heavy losses under Humax ownership, control passed in December 2024 to Beno T&R, an investment-driven KOSDAQ group. Alticast has since been reshaped into a small holding-style vehicle with three parts:
Legacy software and platform business: mobility SaaS (RAiDEA), connected-vehicle IoT, cloud UI, QA services and a blockchain payments subsidiary.
HVAC and fire-protection contractor: Daehyun Gigeon, acquired in April 2025, which now drives most revenue.
Influential stake in Aptamer Sciences: a KOSDAQ bio/CRO company that is pivoting into US premium pet food.
The equity story rests on Daehyun Gigeon's cash generation and option value in the bio/pet-food stake. Against that sit thin margins, recurring dilution, related-party complexity and KOSDAQ listing-maintenance risk.
Company's own description
Recent company statements (March and April 2026 press releases via Asia Economy) still introduce Alticast as a digital broadcasting software specialist. They describe the current portfolio in three pillars:
Cash generation: Daehyun Gigeon (HVAC/fire-protection) is described as the stable cash-generating core.
Growth: Aptamer Sciences is positioned as the growth engine, through drug-delivery technology, CRO services (via ISS) and US pet food (via Choolip).
New business: Subsidiary Altiplatform (알티플랫폼) develops blockchain-based enterprise payment and promotion systems for B2B customers.
Management targets North American expansion and fixed-cost reduction in 2026. Its stated ambition is to become a "quality company" within two to three years.
The S&P business description, last updated October 2026, still reflects the pre-2025 software catalogue. It says Alticast develops mobility services and device platforms, citing RAiDEA, OTOPLUG and AltiCloud UI.
Independent characterisation
Alticast is best understood as a micro-cap holding company with an operating construction-services subsidiary bolted onto a residual software business. The evidence is in the margins:
Gross margin collapse: Consolidated gross margin fell from 94.6% in FY2021 (pure software) to 25.0% in FY2025, and 17.4% on a trailing twelve-month basis to June 2026 (S&P).
What this means: The mix is now dominated by low-margin contracting revenue.
Daehyun Gigeon's scale: Management says Daehyun Gigeon's standalone revenue is in the high-KRW-60 bn range per year. That is larger than the entire consolidated group before the acquisition.
Business model and revenue model
| Business line | Revenue model | Value-chain position | Customer types |
|---|---|---|---|
| HVAC and fire-protection installation (Daehyun Gigeon) | Project/contract revenue, recognised over construction progress (inferred from industry practice; not confirmed in sources) | Specialty subcontractor to general contractors | Tier-1 Korean construction companies (company statement) |
| Mobility SaaS (RAiDEA), IoT (OTOPLUG), cloud UI | Licence, platform fees, SI/customisation (historical disclosures) | Software vendor / platform provider | Mobility operators, car-sharing/rental firms, telcos, STB operators |
| Platform QA / verification services | Service fees | Outsourced QA provider | Telcos and platform operators (e.g., KT contract, see Section 14) |
| Blockchain payments / promotions (Altiplatform) | — | Early-stage B2B platform | Enterprises (B2B) |
| Bio, CRO and pet food (Aptamer Sciences, via stake) | Diagnostics, CRO analytical services, consumer products | Drug-delivery R&D, bioanalytical CRO, branded pet food | Pharma/biotech clients; US pet retail (Amazon, Costco) |
Revenue mix: A product vs. service vs. subscription vs. licensing split is not publicly disclosed in sources reviewed.
End-markets: These are Korean commercial and residential construction (MEP), Korean mobility and telecom software, and drug development services and US pet consumables (via Aptamer).
Strategy
Stated strategy (paraphrased from company releases, March–April 2026)
-
Financial normalisation.
-
Eliminate the accumulated deficit via the 5-to-1 capital reduction and transfer of capital surplus to retained earnings.
-
Shed the "penny stock" image.
-
Comply with tightened KOSDAQ listing-maintenance rules.
-
Create legal capacity for future dividends or treasury-share cancellation.
-
-
Cash-flow anchor. Use Daehyun Gigeon's backlog with tier-1 contractors as the earnings base.
-
Growth via Aptamer Sciences. Drug-delivery R&D, CRO services and the Choolip pet-food platform, with US retail expansion in 2026.
-
Blockchain B2B. Altiplatform's enterprise payment and promotion systems.
-
Cost and geography. North American expansion and fixed-cost reduction expected to take effect in 2026.
-
Medium-term ambition. Become a high-quality company within two to three years. No quantified targets were given.
Initiatives in the last 24 months
| Date | Initiative | Type | Targets / status |
|---|---|---|---|
| Dec 2024–Jan 2025 | Beno T&R recapitalisation (rights issue plus perpetual CB; about KRW 40 bn planned including FIs) | Capital raise | Beno portion completed 24 Dec 2024 |
| Jan 2025 | Blockchain game platform; robotics/AI cooperation with Human in Motion Robotics (Beno affiliate; XoMotion-R exoskeleton) | New business / partnership | No subsequent results disclosed |
| Apr 2025 | Daehyun Gigeon acquisition | M&A / diversification | Completed |
| Sep–Oct 2025 | Aptamer Sciences control investment | M&A | Completed 27 Oct 2025 |
| Sep 2025 | Third-party share issue to Vision2 | Capital raise | Completed 30 Sep 2025 |
| Mar–Apr 2026 | 5-to-1 capital reduction; deficit elimination | Capital restructuring | Effective 8 Apr 2026 |
| Mar 2026 | Choolip acquisition via Aptamer (USD 11.4 m) | M&A (subsidiary level) | Announced 25 Mar 2026 |
| 2,026 | Altiplatform B2B blockchain commercialisation | New business | Pending |
Not disclosed in sources reviewed:
-
Medium-term financial targets / guidance: none publicly quantified.
-
ESG / sustainability commitments: none disclosed.
Products & Services
Software and platforms (parent)
| Product | Description | Key capabilities | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|---|
| RAiDEA (mobility service platform) | All-in-one mobility platform | Station-based and free-floating car sharing, car hailing, rental automation, micro-mobility; round-trip, one-way and free-floating modes; B2C, B2B and P2P (S&P; Aju 2021) | Car-sharing, rental and mobility operators. Reference deployments: Humax Mobility Carplat Biz and WAY (2021) | In commercial use by 2021; latest version not disclosed | — |
| RAiDEA Smart Parking | Smart-parking platform | Introduction, operation, connection and expansion of smart-parking services (S&P) | Parking operators | — | — |
| OTOPLUG | Cloud-based vehicle IoT platform | Connection services with vehicles (S&P) | Fleet and mobility operators, OEM partners | — | — |
| AltiCloud UI | Cloud-rendered user interface | Runs the UI in the cloud and delivers a lightweight presentation layer to STBs and mobile clients (S&P) | Pay-TV operators, device makers | — | — |
| Platform QA / verification services | Quality-verification services for mobility and other platforms | Outsourced testing | Telcos and platform operators | — | Service fees |
| In-car payment / connected-car commerce | Mobility payment services (MyDailyByte summary) | In-car payments | Mobility operators | — | — |
Blockchain (Altiplatform)
| Offering | Description | Status |
|---|---|---|
| Enterprise blockchain payment solution | Blockchain-based corporate payment system | Commercialisation targeted in B2B. Management expected visible results soon as of March 2026. |
| Promotion system | Blockchain-based promotions | As above |
| Blockchain game platform | Announced as a strategic direction after the Beno T&R investment (Jan 2025) | Status not disclosed |
HVAC and fire protection (Daehyun Gigeon)
| Offering | Description | Customers |
|---|---|---|
| HVAC (air-conditioning and ventilation) installation | Mechanical equipment installation as a specialty contractor | Tier-1 Korean general contractors |
| Fire-protection systems | Fire-protection equipment installation | As above |
Order backlog: Management states the backlog is rising. A specific figure is not disclosed.
Bio, CRO and pet food (Aptamer Sciences, via stake)
| Product / service | Description | Status |
|---|---|---|
| Aptamer drug-delivery platforms | AlloMAp (allosteric modulator aptamer) and BiFAp (bi-functional aptamer) platforms, including BBB-shuttle and chimeric aptamer approaches | Research / preclinical; lead pipeline AST-201 in clinical testing per the company (Money Today, Jul 2025) |
| AptoDetect-Lung | Blood-based lung-cancer early-detection kit using a seven-protein aptamer panel | Korean MFDS Class III approval, September 2017 |
| Bioanalytical CRO (ISS) | Preclinical and clinical sample analysis | Merged via small-scale merger effective 19 Aug 2024 |
| Research reagents and samples distribution | Distribution business expanded to secure revenue base | Ongoing |
| Squeeze Vita Stick (Choolip) | Creamy paste pet treat with 30+ vitamins and nutrients, positioned around organ-specific nutrition | Sold on Amazon and at Costco |
| Berry Good Milk (Choolip) | Vitamin-fortified, lactose-free pet milk | Ranked first in the cat new-product showcase at SuperZoo 2024 |
ISS background. International Scientific Standard was founded in 2008 as a joint venture of Battelle Memorial Institute and Yuyu Pharma. Its purchase price was reported as within KRW 2 bn.
Choolip scale and plans:
-
2025 Amazon sales of 94,789 units and about USD 2.83 m in orders (Money Today, Mar 2026).
-
Planned 2026 retail expansion targets reported by Asia Economy: Walmart (500–900 stores), TJ Maxx (5,000), Petco (1,300) and Target (500).
Name change flag. The IRGO investor-relations portal lists Aptamer Sciences' IR room under the name "Choolip & Science" (츌립앤사이언스). This suggests a 2026 corporate rename, but it is not independently confirmed.
Divested legacy products (for reference)
The following were sold with Altimedia to KT in 2021 and are no longer Alticast products:
-
Digital broadcast middleware
-
CAS/DRM
-
Server solutions
-
UI/UX
-
Applications
-
Browsers
-
HTML5 smart package
-
RDK-based solutions
-
Software CAS
Financial Narrative
Source for all tables: S&P Global Market Intelligence via StockAnalysis.com (annual data, fiscal years ending 31 December; KRW millions; per-share data adjusted for the April 2026 1-for-5 reverse split).
Income statement
Notes:
-
Company-reported FY2025 operating profit is KRW 3.2 bn vs. S&P's KRW 1.909 bn.
-
FY2022 also includes a KRW 3.70 bn goodwill impairment and KRW 4.03 bn loss on investment sales.
-
FY2023 includes KRW 7.21 bn loss on investment sales.
-
FY2024 includes KRW 4.51 bn loss on investment sales.
Dividend flag: One aggregator (Eulerpool) displays a dividend yield of about 46.7%. S&P and the cash-flow statement record no dividends paid. The aggregator figure is treated as a data error.
Margins
Revenue CAGR:
Both CAGRs are acquisition-driven and not organic. Organic revenue in the legacy software business fell about 84% between FY2021 and FY2024.
Balance sheet
Notes:
Equity series: Total equity is shown as total assets minus total liabilities. S&P's "total common equity" line is internally inconsistent for FY2022–FY2023 and is not used.
Trading securities: FY2025 cash plus short-term investments includes KRW 12.09 bn of trading securities.
30 June 2026 balance sheet (TTM column): - Total assets KRW 80.89 bn
-
Cash and short-term investments KRW 10.79 bn
-
Total debt KRW 13.55 bn, giving net debt of KRW 2.75 bn
-
Equity KRW 50.55 bn
-
Common stock reduced to KRW 7.15 bn and retained earnings turned positive at KRW 6.55 bn, consistent with the capital reduction and reserve transfer
Cash flow
TTM to June 2026: Operating cash flow was KRW –6.69 bn and free cash flow KRW –6.79 bn. Working capital absorbed KRW 11.6 bn, consistent with a growing construction receivables book.
Ratios
Net debt / EBITDA: This is meaningful only in years with positive EBITDA: FY2021 –2.58x and FY2025 –4.63x (both net cash).
TTM to June 2026: Net debt / EBITDA is about 2.0x on KRW 1.37 bn EBITDA.
Cash conversion cycle: Not computable from available data; inventory is immaterial, and payables were not reported before FY2025. Not publicly disclosed.
Receivable days: Calculated as accounts receivable ÷ revenue × 365, using S&P accounts receivable.
Trailing performance (TTM to 30 June 2026)
Derived from the change in TTM: Q2 2026 revenue was about KRW 5.2 bn higher than Q2 2025, while Q2 2026 operating income was about KRW 1.7 bn lower. This points to a weak, loss-making Q2 2026 despite the full-quarter Daehyun contribution.
Commentary on trends, inflections and drivers
-
FY2021–FY2022 collapse.
-
The sale of the media business to KT (agreed April 2021, closed December 2021) removed the core revenue engine.
-
Revenue fell from KRW 36.3 bn to KRW 7.2 bn.
-
The remaining mobility/EV-charging ventures did not scale, as shown by the KRW 3.7 bn goodwill impairment in FY2022 and recurring discontinued-operations losses.
-
-
FY2022–FY2024 cash burn and balance-sheet erosion.
-
Total equity fell from KRW 64.7 bn to KRW 30.0 bn by FY2023.
-
Repeated losses on investment disposals (KRW 4.0 bn, 7.2 bn, 4.5 bn) and equity-method losses (KRW 4.2 bn, 6.3 bn) indicate a portfolio of non-core financial investments that destroyed value.
-
The FY2023 current ratio dipped below 1.0x.
-
-
FY2024 recapitalisation.
-
The Beno T&R-led rights issue and perpetual CB brought in about KRW 25.8 bn of FY2024 financing inflows (KRW 10.5 bn common stock plus KRW 15.3 bn other financing).
-
Cash was restored to KRW 23.3 bn and debt cut to KRW 3.8 bn.
-
-
FY2025 inflection.
-
The Daehyun Gigeon acquisition drove revenue up about 9x and returned the group to a small operating profit.
-
The trade-off is a structurally lower margin profile: 25% gross and 3.6–6% operating (S&P vs. company).
-
Cash outflow for acquisitions (KRW 16.2 bn) consumed most of the 2024 capital raise.
-
-
2026 deterioration.
-
TTM operating income turned negative by June 2026.
-
Net debt re-emerged at KRW 2.75 bn, and short-term debt rose to KRW 10.1 bn.
-
Gross margin compressed to 17.4%. The recovery narrative has not yet translated into sustained earnings or cash generation.
-
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Operating Unit Details
| Operating unit | Legal entity | Contents | Ownership | Consolidation status |
|---|---|---|---|---|
Software and platforms | Alticast Corporation (parent) | RAiDEA mobility and parking SaaS, OTOPLUG vehicle IoT, AltiCloud UI, platform QA/verification services | 100% | Parent |
Blockchain payments | Altiplatform (알티플랫폼) | Blockchain-based enterprise payment and promotion systems | Described as a subsidiary; % not disclosed | Not confirmed |
HVAC and fire protection | Daehyun Gigeon (대현기건) | Mechanical HVAC and fire-protection installation; about 40-year operating history | Acquired April 2025; % not disclosed | Consolidated, inferred from the FY2025 revenue step-up and new goodwill/intangibles |
Bio, CRO and pet food | Aptamer Sciences (압타머사이언스) | Aptamer-based drug delivery and diagnostics; bioanalytical CRO via merged ISS; Choolip US pet food | 17.59% direct at 27 Oct 2025, plus related-party holdings (see note below) | Described by the company as a "subsidiary"; accounting treatment not confirmed. FY2025 shows KRW 1.85 bn of equity-method losses and KRW 3.2 bn minority interest, so both treatments are plausible for different stakes. |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consolidated revenue (KRW Mn) | 5,658 | 5,681 | 53,166 |
Consolidated operating income (KRW Mn) | -9,609 | -5,240 | 1,909 |
Operating margin (%) | -169.81 | -92.25 | 3.59 |
Revenue YoY growth (%) | -21.90 | 0.40 | 835.91 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 36,254 | 7,245 | 5,658 | 5,681 | 53,166 |
Revenue growth (%) | -17.79 | -80.02 | -21.90 | 0.40 | 835.91 |
Cost of revenue (KRW Mn) | 1,962 | 159 | 4 | 3,260 | 39,858 |
Gross profit (KRW Mn) | 34,292 | 7,086 | 5,654 | 2,420 | 13,308 |
SG&A (KRW Mn) | 27,742 | 14,778 | 8,515 | 5,584 | 8,338 |
Operating income — S&P (KRW Mn) | 193 | -9,958 | -9,609 | -5,240 | 1,909 |
EBITDA (KRW Mn) | 3,837 | -8,730 | -8,737 | -4,388 | 3,135 |
D&A (KRW Mn) | 3,643 | 1,228 | 871 | 852 | 1,225 |
Interest expense (KRW Mn) | 417 | 1,110 | 1,400 | 1,598 | 413 |
Equity-method income (KRW Mn) | 0 | 0 | -4,200 | -6,281 | -1,848 |
Pre-tax income (KRW Mn) | 3,170 | -16,389 | -20,037 | -15,827 | 856 |
Income tax (KRW Mn) | 2,387 | 6 | 84 | 59 | 843 |
Discontinued operations (KRW Mn) | -5,694 | -1,740 | -6,388 | 2,612 | 0 |
Net income attributable to parent (KRW Mn) | -4,911 | -17,817 | -25,974 | -13,032 | -813 |
EPS basic, split-adjusted (KRW) | -860.71 | -3,081.95 | -4,492.87 | -2,196.38 | -78.44 |
EPS diluted, split-adjusted (KRW) | -860.71 | -3,081.95 | -4,492.87 | -2,196.38 | -78.44 |
Dividends per share (KRW; 0 = no payment recorded) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 94.59 | 97.81 | 99.93 | 42.60 | 25.03 |
Operating margin — S&P (%) | 0.53 | -137.46 | -169.81 | -92.25 | 3.59 |
EBITDA margin (%) | 10.58 | -120.50 | -154.42 | -77.24 | 5.90 |
Net margin (%) | -13.55 | -245.94 | -459.04 | -229.42 | -1.53 |
Calculation by Period
| Period | Calculation | CAGR |
|---|---|---|
FY2021–FY2025 (4-year) | (53,166 / 36,254)^(1/4) – 1 | ≈ 10.0% |
FY2020–FY2025 (5-year) | Using FY2020 revenue of KRW 44.5 bn (Aju/DART) | ≈ 3.6% |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Mn) | 83,176 | 69,961 | 50,186 | 44,794 | 74,856 |
Cash and equivalents (KRW Mn) | 23,221 | 989 | 1,308 | 23,318 | 6,997 |
Cash and short-term investments incl. trading securities (KRW Mn) | 23,320 | 1,078 | 1,308 | 23,318 | 21,120 |
Short-term debt incl. current lease and current LTD (KRW Mn) | 3,808 | 2,026 | 10,301 | 3,408 | 5,086 |
Long-term debt incl. long-term leases (KRW Mn) | 9,595 | 8,506 | 6,530 | 344 | 1,533 |
Total debt (KRW Mn) | 13,402 | 10,532 | 16,831 | 3,753 | 6,619 |
Net debt (KRW Mn; negative = net cash) | -9,918 | 9,454 | 15,524 | -19,565 | -14,501 |
Total shareholders' equity (KRW Mn) | 64,748 | 55,746 | 30,010 | 36,850 | 54,011 |
Goodwill and other intangibles (KRW Mn) | 11,088 | 7,328 | 3,740 | 9 | 6,113 |
Long-term investments (KRW Mn) | 33,690 | 35,835 | 27,476 | 16,237 | 25,806 |
Working capital (KRW Mn) | 22,550 | 5,850 | -1,493 | 20,971 | 20,611 |
Book value per share, split-adjusted (KRW) | 11,452.60 | 8,452.50 | 3,962.28 | 3,816.50 | 4,129.22 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Mn) | -3,211 | -8,833 | -3,770 | -3,836 | -2,155 |
Capital expenditure (KRW Mn, outflow negative) | -477 | -265 | -24 | -31 | -410 |
Free cash flow (KRW Mn) | -3,688 | -9,098 | -3,795 | -3,867 | -2,565 |
Cash acquisitions (KRW Mn) | 8,997 | -193 | 0 | -8 | -16,245 |
Divestitures (KRW Mn) | 13,239 | 0 | 0 | 0 | 0 |
Common stock issued (KRW Mn) | 0 | 0 | 0 | 10,539 | 5,999 |
Other financing incl. hybrid / perpetual CB (KRW Mn) | 0 | 864 | -19 | 15,251 | 6,900 |
Dividends paid (KRW Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Mn) | -183 | 0 | 0 | 0 | 0 |
Net change in cash (KRW Mn) | 5,904 | -22,232 | 319 | 22,010 | -16,321 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 1.17 | -27.21 | -46.93 | -47.52 | 0.03 |
ROA — S&P (%) | 0.14 | -8.13 | -10.00 | -6.90 | 1.99 |
ROIC (%) | 0.08 | -16.59 | -17.35 | -16.68 | 0.10 |
Current ratio (x) | 4.25 | 2.45 | 0.87 | 3.95 | 2.13 |
Quick ratio (x) | 3.91 | 1.56 | 0.39 | 3.62 | 1.54 |
Debt / equity (x) | 0.21 | 0.19 | 0.56 | 0.10 | 0.12 |
Interest coverage, EBIT / interest (x) | 0.46 | -8.97 | -6.86 | -3.28 | 4.63 |
Asset turnover (x) | 0.43 | 0.10 | 0.09 | 0.12 | 0.89 |
Receivable days, derived (days) | 30 | 149 | 178 | 124 | 47 |
Income Statement
| Metric | TTM Mar-2026 | TTM Jun-2026 |
|---|---|---|
Revenue (KRW Mn) | 69,026 | 74,269 |
Gross profit (KRW Mn) | 14,439 | 12,900 |
Operating income — S&P (KRW Mn) | 1,378 | -289 |
Net income attributable (KRW Mn) | not shown | -5,404 |
Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (KRW Mn) | 5,658 | 5,681 | 53,166 |
Region Overview
| Region | Exposure | Evidence | Direction |
|---|---|---|---|
South Korea | Near-total: construction services (Daehyun Gigeon), domestic mobility/telecom software and QA (e.g., KT contract) | Business composition | Growing (acquisition-driven) |
North America | Emerging: management targets North American expansion in 2026; Aptamer's Choolip operates from California and sells via Amazon/Costco | Asia Economy, Mar 2026; Money Today, Mar 2026 | New. It reaches Alticast only if Aptamer is consolidated, or indirectly via equity value. |
Vietnam, Netherlands, Turkey (historical) | Legacy media-software footprint (Viettel, Türk Telekom clients) | Aju, Dec 2021 | Exited with the Altimedia sale to KT in 2021 |
Capital Markets Data (KRW) and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end close, split-adjusted (KRW) | 12,125 | 8,800 | 5,610 | 5,980 | 2,935 |
Year-end market capitalisation (KRW Mn) | 70,097 | 50,875 | 32,433 | 36,241 | 35,235 |
Year-end enterprise value (KRW Mn) | 65,998 | 57,743 | 52,187 | 54,114 | 6,404 |
Year-end P/S (x) | 1.93 | 7.02 | 5.73 | 6.38 | 0.66 |
Year-end P/B (x) | 1.08 | 0.91 | 1.08 | 0.98 | 0.65 |
Year-end EV/Sales (x) | 1.82 | 7.97 | 9.22 | 9.53 | 0.12 |
Shares outstanding, split-adjusted (M) | 5.78 | 5.78 | 5.78 | 9.66 | 12.30 |
Change by Period
| Period | Change | Basis |
|---|---|---|
1-year | –54.8% | S&P 52-week change at 9 Sep 2026 |
Since FY2023 close (≈3 years) | –75.0% | vs. KRW 5,610 |
Since FY2021 close (≈5 years) | –88.4% | vs. KRW 12,125 |
Valuation Multiples
| Multiple | Alticast (Sep–Oct 2026) |
|---|---|
P/E | Not meaningful (TTM loss) |
EV/EBITDA | Not meaningful TTM (EBITDA KRW 1.37 bn implies about 19x on EV KRW 26.3 bn) |
EV/Sales | 0.35x |
P/B | 0.40–0.42x |
P/TBV | 0.51–0.52x |
P/S | 0.28x |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None (S&P: no analysts, no price target) |
Dividend history | No dividends recorded FY2021–FY2025 (S&P). Policy: none paid; capital reduction intended to enable future dividends or treasury-share cancellation (company). |
Buyback authorisations | None disclosed. Last recorded repurchase KRW 183 m in FY2021; treasury share cancellation of 157,000 shares reported (undated). |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | Not disclosed. At June 2026: short-term debt KRW 10.1 bn, current portion of long-term debt KRW 1.76 bn, long-term debt KRW 1.04 bn, leases KRW 0.64 bn (S&P). About 87% of debt is due within 12 months. |
Analyst Conclusions
Management guidance and consensus
Management guidance: No quantified guidance. Management expects North American expansion and lower fixed costs to improve stability in 2026. It targets "quality company" status within two to three years (Asia Economy, Mar–Apr 2026).
Consensus: No sell-side coverage; consensus not available.
Bull case
-
Earnings floor. Daehyun Gigeon's high-KRW-60 bn annual revenue and growing backlog give a durable floor. A full-year FY2026 consolidation could lift revenue toward the KRW 70–80 bn TTM run-rate (S&P TTM KRW 74.3 bn).
-
Deep discount to assets. At about 0.4x book and 0.5x tangible book, the market assigns little value to the Aptamer stake, the KRW 23 bn of long-term investments or the KRW 7.8 bn of land and buildings.
-
Financial clean-up done. Deficit elimination and the reverse split remove technical overhangs. Any return to profit could support first-ever distributions.
Bear case
-
Earnings quality is poor and deteriorating. TTM operating income turned negative, gross margin fell to 17.4%, and free cash flow has been negative for five straight years.
-
Governance and control risk dominates. Alticast sits under Beno T&R, whose own control sale is delayed. Related parties co-invest alongside the company, and the shareholder base has absorbed about 75% (FY2025) and about 50% (TTM) dilution.
-
Listing-maintenance pressure is acute. Market cap of about KRW 19–20 bn is at or below the new KOSDAQ minimum and well below the KRW 30 bn bar from January 2027. This creates pressure for further equity issuance or corporate actions that may not favour minorities.
Catalysts and monitorables (next 12 months)
| Monitorable | What to watch |
|---|---|
| Beno T&R change of control | Completion of the Acro New Technology Fund No. 241 transaction and any knock-on change in Alticast's board or strategy |
| KOSDAQ market cap | Sustained trading above KRW 20 bn, and progress toward the KRW 30 bn requirement before January 2027 |
| Q3 2026 results (due about mid-November 2026) | Whether operating profit recovers; Daehyun margins; receivables trend |
| Aptamer Sciences / Choolip | Choolip closing; US retail roll-out (Walmart, Petco, Target, TJ Maxx); Aptamer's consolidation treatment and share price |
| Capital raising | Any new third-party allotments, CBs or perpetual instruments |
| Altiplatform | First disclosed B2B blockchain contracts |
| Shareholder returns | Any dividend or treasury-share cancellation now that the deficit is cleared |
Analyst verdict
Alticast Corporation today bears little resemblance to the company that listed on KOSDAQ in December 2013. The broadcast-middleware franchise that once generated KRW 65 bn of revenue and double-digit margins was sold to KT in 2021 for about KRW 11 bn. Three years of losses followed: cumulative net losses of roughly KRW 57 bn between FY2022 and FY2024.
The December 2024 entry of Beno T&R, and the 2025 acquisitions of Daehyun Gigeon and a controlling position in Aptamer Sciences, have produced a headline turnaround. Revenue rose ninefold to KRW 53.2 bn in FY2025, and operating profit of KRW 1.9–3.2 bn was the first in four years. A 5-to-1 capital reduction has cleaned up the accumulated deficit.
Underneath, the picture is less convincing:
Acquired growth: The growth is acquired, not organic, and comes at contractor-level margins.
Relapse: TTM operating income was already back in the red by June 2026, and free cash flow has been negative for five consecutive years.
Funding by dilution: Growth has been funded through repeated dilutive placements.
Complex governance: The structure involves a listed parent whose own control is changing hands, related parties investing alongside the company, and limited governance disclosure. This warrants a substantial discount.
The valuation reflects that scepticism. At 0.4x book and about 0.3x sales, the shares price in either continued value leakage or a high probability of further dilution. The most pressing near-term issue is mechanical rather than fundamental. Market capitalisation of about KRW 19–20 bn sits at the new KOSDAQ minimum and well short of the KRW 30 bn bar that applies from January 2027. That raises the odds of further corporate actions whose terms may favour insiders.
Verdict: Alticast is a speculative special situation, not an investment-grade operating story. Deep-value investors could find asset backing attractive only with clear evidence of three things:
-
Sustained positive operating cash flow at Daehyun Gigeon.
-
A stable, completed change of control at Beno T&R.
-
A credible plan to clear the 2027 listing threshold without further heavy dilution.
Until then, governance and listing risks outweigh the balance-sheet discount.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background |
|---|---|---|
Chung Wook-jae (정욱재) | CEO / Representative Director | Executive director and CFO at the 2013 IPO (eToday, Nov 2013); now CEO (S&P; Asia Economy, Mar 2026). Start date as CEO not disclosed. |
Chung Jip-hoon (정집훈) | Co-Representative Director (per TheVC and Jasoseol) | CEO of Beno T&R; certified public accountant (Sidae, 2023); held 26.73% of Lamicus as of 2023 |
Kang Won-chul (강원철) | Former CEO | CEO at 2013 IPO |
Seo Jung-kyu (서정규) | Former CEO | CEO during the Humax-era sale process; reported to have faced a breach-of-trust complaint |
Major Shareholders
| Holder | Stake | Date / basis | Source |
|---|---|---|---|
Beno T&R Co., Ltd. | Largest shareholder; % not disclosed in sources reviewed | Since Dec 2024 | Asia Economy |
Vision2 Co., Ltd. (비전2) | 15.01% (9,124,086 pre-reduction shares) | 30 Sep 2025 | Digital Today |
Insiders (aggregate) | 2.38% | S&P, Sep 2026 | S&P |
Free float | 3.71 m shares (~26.5% of 13.98 m) | S&P, Sep 2026 | S&P |
Treasury shares | Carried at KRW 3.12 bn (FY2025); TheVC headline reports cancellation of 157,000 common shares (date not stated) | — | S&P; TheVC |
Governance Detail
| Step | Detail | Source |
|---|---|---|
Beno T&R's controller | Lamicus became Beno T&R's largest shareholder in March 2023 with 15.79% | Sidae |
Lamicus ownership | Lamicus's largest shareholder is investor Park Hyung-jun (73.27%), described in press as an M&A specialist and referred to as "chairman". Not to be confused with the Busan politician of the same name. | Sidae, 2023 |
Related vehicle | Press reports link Park to J&J Investment, through which he acquired Beno T&R and JK Synapse | TheVC news index |
Sale agreement (3 Jul 2026) | Lamicus and Chung Jip-hoon agreed to sell 4,782,496 Beno T&R shares (12.75%) to Acro New Technology Fund No. 241 at KRW 7,100/share (about KRW 33.96 bn) | Edaily; Chosun Biz |
Accompanying placement | KRW 10 bn placement of 11,737,089 new Beno T&R shares at KRW 852 | Edaily; Chosun Biz |
Premium controversy | Press criticised the control premium (reported at about 600%) relative to the discounted new-share issue | Chosun Biz |
Payment status | KRW 10 bn deposit paid. The KRW 23.96 bn balance was postponed from 27 Aug to 14 Sep 2026; a further Acro placement is scheduled for 23 Dec 2026. | Dealsite, Aug 2026 |
Completion | Not confirmed in sources reviewed as of 15 Oct 2026 | — |
Competitive Landscape
Competitors by Segment
| Segment | Named competitors / peers | Basis |
|---|---|---|
Media / platform software (residual) | KT Altimedia (Alticast's former media business), TVStorm (티비스톰), Birdland Software (버드랜드소프트웨어), ERmind (이알마인드), Castis (캐스트이즈, VOD/media delivery) | TheVC peer mapping; Wanted company profile |
Mobility SaaS | Humax Mobility group (historical partner and potential competitor) | Aju, 2021 |
HVAC / fire-protection subcontracting | Specific competitors not identified in sources reviewed | Fragmented Korean specialty-contractor market |
Bioanalytical CRO / aptamer therapeutics (Aptamer) | Specific competitors not identified in sources reviewed | — |
US premium pet food (Choolip) | Specific competitors not identified in sources reviewed | — |
Peer Comparison FY2025
| Metric | Alticast (FY2025) | KT Altimedia |
|---|---|---|
Revenue | KRW 53.2 bn | — |
Revenue growth | +835.9% | — |
Operating margin | 3.6% (S&P) / about 6.0% (company) | — |
Employees | 39–71 | 178 (TheVC, Jun 2026) |
“—” = not publicly disclosed.



